Clavis Pharma makes board appointments
This article was originally published in Scrip
Executive Summary
The Norwegian cancer drug development company Clavis Pharma has elected Anders Wiklund and Annette Clancy to serve on its board of directors as chairman and non-executive director, respectively. The appointments were made at Clavis's annual general meeting held in Oslo on 20 May, when former chairman Keith McCullagh, Gert Caspritz and Stina Gestrelius also stepped down from the board. Mr Wiklund has 40 years' business and corporate development experience in the biotechnology and pharmaceutical industries. He spent 29 years with the Kabi and Pharmacia group of companies, where he served in a number of positions, including managing director of KabiVitrum (UK), president of KabiVitrum International (Sweden), and president and CEO of KabiVitrum and KabiPharmacia (US). In 1997, he founded Wiklund International, an advisory firm to the biotech industry, and co-founded Esperion Therapeutics and served for several years on its board of directors before its acquisition by Pfizer for $1.3 billion. Ms Clancy has more than 25 years' experience in the pharmaceutical industry, predominantly with GlaxoSmithKline, where she worked in a variety of functions, including R&D, strategic marketing and licensing/business development. She currently serves as a senior advisor at the US-based venture capital firm Frazier Healthcare Ventures, as chair of GSK's respiratory R&D team and as a non-executive director at Silence Therapeutics.
You may also be interested in...
Morgan Lewis expands FDA & healthcare practice
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma appoints new member to board
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
Optimer expands management team
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.